Nedaplatin-based concurrent chemoradiotherapy is noninferior to cisplatin-based therapy in patients with locoregional nasopharyngeal carcinoma
1. Patients receiving either nedaplatin-based or cisplatin-based concurrent chemoradiotherapy had no significant difference in progression free survival at five years....